(Yicai Global) Dec. 7 -- Walvax Biotechnology Co. [SHE:300142], which based in southwestern China's Yunnan province, about to conclude its clinical research into self-developed 13-valent pneumococcal conjugate vaccine, in the hope that it can grasp a share of the market mostly dominated by US-based Pfizer, Inc. [NYSE:PFE].>
The firm has completed the initial data analys in Phase III clinical trial in its reserach, and engaging in the analys of clinical trial data and the summary of clinical research, said the company in a statement sued yesterday.
After acquiring the summary report of the clinical research into vaccine, Walvax can file an application to China food and drug admintration (CFDA) for drug production approval letter. Such a letter and GMP certification will allow the firm to start manufacturing and sell the product on the market with a batch release certificate, said the statement. The lted company well-prepared for the preliminary work required for obtaining the production approval letter for the vaccine, it added.
The 13-valent pneumococcal conjugate vaccine, designed for preventing the invasive deases caused by the infection of 13 kinds of serotype pneumococcus in vaccines, enjoys a better sales performance than any other variety of vaccines worldwide. At present, only Pfizer produces and sells 13-valent pneumococcal conjugate vaccine worldwide, whose global sales exceeded USD5.7 billion in 2016.